QR code

Afatinib and Necitumumab in EGFR-Mutant NSCLC with Acquired Resistance to Tyrosine Kinase Inhibitors

Introduction: Although tyrosine kinase inhibitors (TKIs) are effective against NSCLC harboring sensitizing EGFR gene mutations, acquired resistance is inevitable. Preclinical studies suggest that combining EGFR TKI and monoclonal antibody therapies may have activity in EGFR-mutated NSCLC that has pr...

Volledige beschrijving

Bewaard in:
Hoofdauteurs: Nathaniel J. Myall, MD, Jennifer G. Whisenant, PhD, Joel W. Neal, MD, PhD, Wade T. Iams, MD, Karen L. Reckamp, MD, Sally York, MD, PhD, Lynne D. Berry, PhD, Yu Shyr, PhD, Leora Horn, MD, Heather A. Wakelee, MD, Sukhmani K. Padda, MD
Formaat: Artigo
Taal:Inglês
Gepubliceerd in: Elsevier 2025-02-01
Reeks:JTO Clinical and Research Reports
Onderwerpen:
Dual EGFR inhibition
Phase I trial
Lung cancer
EGFR-mutated
Online toegang:http://www.sciencedirect.com/science/article/pii/S2666364324001279
Tags: Voeg label toe
Geen labels, Wees de eerste die dit record labelt!

Gelijkaardige items